Some surgical aspects of gynecologic cancer.
The most important developments in gynecologic oncology in recent years have been the advent of supervoltage irradiation that allows the delivery of better and safer therapy; the diligent search for new cancerostatic drugs and hormones and their clinical application, singly and in combination; and studies suggesting the possibility of immunotherapy. Conversely, few noteworthy developments have emerged in the operative management of gynecologic malignancy, even though refinements of surgical technique, improved preoperative and postoperative care, and better control of infectious problems gradually have decreased the operative morbidity and mortality rates and have improved the survival rates significantly. Surgery continues to be the dominant therapy. Irradiation, chemotherapy, and hormones are therapeutic adjuvants in the management of ovarian, endometrial, cervical, vulvar, and other genital malignancies. As a result of earlier diagnosis, with the greatly diminished incidence of far-advanced carcinoma of the cervix, primary surgery is having a larger role in the management of the early stages of this lesion. Aggressive surgical removal of advanced, dissemenated ovarian carcinoma is worthwhile; diminishing the volume of the lesion significantly improves the response of residual tumor to adjuvant therapy.
D000230:Adenocarcinoma / Q000601:surgery; D002277:Carcinoma / Q000601:surgery; D002278:Carcinoma in Situ / Q000601:surgery; D003536:Cystadenocarcinoma / Q000601:surgery; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000601:surgery* / Q000628:therapy; D002583:Uterine Cervical Neoplasms / Q000601:surgery*; D014594:Uterine Neoplasms / Q000532:radiotherapy / Q000601:surgery*